One of the key catalysts to come, as described by others above, is the partnering with a bigger pharma for the clinical trials.
Ann: PAT-DX1 significantly improves survival in aggressive GBM, page-40
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $3.293K | 1.023M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 28067181 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25555973 | 16 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |